Is CYP2D6 useful for Wechseljahre?

CYP2D6 is a drug-metabolizing enzyme relevant for tamoxifen and certain antidepressants. For menopause (Wechseljahre), there is no direct genetic recommendation. Its utility is limited to personalized metabolism of hormone replacement therapy or co-medications. Evidence is weak: no validated polygenic scores or clinical guidelines recommend CYP2D6 testing for menopause. MyBody-X tests may genotype CYP2D6, but the benefit is unclear. Testing could be considered only if specific drug therapy (e.g., tamoxifen for breast cancer risk) is planned. Without such medication, the test offers no clinical value for menopause management. Be cautious of marketing claims that overstate its relevance.